Skip to main content
Fig. 1 | BMC Pulmonary Medicine

Fig. 1

From: Efficacy of benralizumab for patients with severe eosinophilic asthma: a retrospective, real-life study

Fig. 1

GETE scores. The GETE scores for the following five settings: all patients (n = 24, 1st (upper)), without previous mepolizumab treatment (n = 13, 2nd), with previous mepolizumab treatment (n = 11, 3rd), without AERD (n = 13, 4th) and with AERD (n = 11, 5th (bottom)). Except for the AERD group, the response rates to benralizumab were approximately 60–70%. Abbreviations: GETE, Global Evaluation of Treatment Effectiveness, AERD, aspirin-exacerbated respiratory disease

Back to article page